Skip to main content
SpringerLink
Log in

Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to monitor the metabolic effects of temozolomide (TMZ) chemotherapy in malignant gliomas by means of repeated positron emission tomography (PET) with [11C]methionine (MET).

Methods

Fifteen patients with histologically proven malignant glioma were treated by TMZ chemotherapy. MET-PET studies were performed before and after the third cycle of TMZ chemotherapy in all patients, and in 12 patients also after the sixth cycle. Gadolinium-enhanced MRI studies were performed in 12 patients before the first and after the sixth cycle. Clinical status was assessed by the modified Rankin scale. Long-term outcome was assessed by calculating the time to progression (TTP) in months.

Results

Decline in MET uptake during therapy corresponded to a stable clinical status. The median TTP was significantly longer in patients with decline in MET uptake than in those with increasing MET uptake (23 vs 3.5 months; p=0.01, log rank test). There was no significant correlation between change in MET uptake and change in contrast enhancement during treatment for all patients.

Conclusion

The present data demonstrate that clinical stability, which is often achieved under TMZ chemotherapy of malignant glioma, corresponds to a decline in or stability of tumour amino acid metabolism. Tumour responses can already be demonstrated with MET-PET after three cycles of chemotherapy, and absence of progression at that time indicates a high probability of further stability during the next three cycles. A reduction in MET uptake during TMZ treatment predicts a favourable clinical outcome. Molecular imaging of amino acid uptake by MET-PET offers a new method of measurement of the biological activity of recurrent glioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2001;2(9):552–60

    Article  PubMed  CAS  Google Scholar 

  2. DeAngelis LM. Benefits of adjuvant chemotherapy in high-grade gliomas. Semin Oncol 2003;30 (6 Suppl 19):15–18

    Article  PubMed  CAS  Google Scholar 

  3. Ataman F, Poortmans P, Stupp R, Fisher B, Mirimanoff RO. Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. Eur J Cancer 2004;40(11):1724–30

    Article  PubMed  CAS  Google Scholar 

  4. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000;1(5):459–68

    Article  PubMed  CAS  Google Scholar 

  5. Grant R, Liang BC, Slattery J, Greenberg HS, Junck L. Chemotherapy response criteria in malignant glioma. Neurology 1997;48(5):1336–40

    PubMed  CAS  Google Scholar 

  6. Levivier M, Becerra A, De Witte O, Brotchi J, Goldman S. Radiation necrosis or recurrence. J Neurosurg 1996;84(1):148–9

    PubMed  CAS  Google Scholar 

  7. Cairncross JG, Macdonald DR, Pexman JH, Ives FJ. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 1988;38(5):724–6

    PubMed  CAS  Google Scholar 

  8. Ostergaard L, Hochberg FH, Rabinov JD, Sorensen AG, Lev M, Kim L, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 1999;90(2):300–5

    Article  PubMed  CAS  Google Scholar 

  9. Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988;62(6):1074–8

    Article  PubMed  CAS  Google Scholar 

  10. Brock CS, Young H, O’Reilly SM, Matthews J, Osman S, Evans H, et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000;82(3):608–15

    Article  PubMed  CAS  Google Scholar 

  11. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-11-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33(11):1972–80

    PubMed  CAS  Google Scholar 

  12. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-11-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39(5):778–85

    PubMed  CAS  Google Scholar 

  13. Nuutinen J, Sonninen P, Lehikoinen P, Sutinen E, Valavaara R, Eronen E, et al. Radiotherapy treatment planning and long-term follow-up with [11C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 2000;48(1):43–52

    Article  PubMed  CAS  Google Scholar 

  14. Würker M, Herholz K, Voges J, Pietrzyk U, Treuer H, Bauer B, et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 1996;23(5):583–6

    Article  PubMed  Google Scholar 

  15. Voges J, Herholz K, Holzer T, Würker M, Bauer B, Pietrzyk U, et al. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg 1997;69(1–4 Pt 2):129–35

    Article  PubMed  CAS  Google Scholar 

  16. Shintani S, Tsuruoka S, Shiigai T. Serial positron emission tomography (PET) in gliomatosis cerebri treated with radiotherapy: a case report. J Neurol Sci 2000;173(1):25–31

    Article  PubMed  CAS  Google Scholar 

  17. Herholz K, Kracht LW, Heiss WD. Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 2003;13(3):269–71

    Article  PubMed  CAS  Google Scholar 

  18. Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50(5):1316–22

    PubMed  CAS  Google Scholar 

  19. Tovi M, Lilja A, Bergstrom M, Ericsson A, Bergstrom K, Hartman M. Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol 1990;31(5):417–29

    Article  PubMed  CAS  Google Scholar 

  20. Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10(21):7163–70

    Article  PubMed  CAS  Google Scholar 

  21. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128(Pt 3):678–87

    Article  PubMed  Google Scholar 

  22. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med 1997;38(2):280–7

    PubMed  CAS  Google Scholar 

  23. Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T. Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo) 1998;38(6):342–7; discussion 347–8

    Article  CAS  Google Scholar 

  24. Kim do K, Kanai Y, Choi HW, Tangtrongsup S, Chairoungdua A, Babu E, Tachampa K, Anzai N, Iribe Y, Endou H. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta 2002;1565 (1):112–121

    Article  PubMed  Google Scholar 

  25. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42 (3):432–445

    PubMed  CAS  Google Scholar 

  26. Bustany P, Chatel M, Derlon JM, Darcel F, Sgouropoulos P, Soussaline F, Syrota A. Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11–L–Methionine. J Neurooncol 1986;3 (4):397–404

    Article  PubMed  CAS  Google Scholar 

  27. Berger G, Maziere M, Knipper R, Prenant C, Comar D. Automated synthesis of 11C-labelled radiopharmaceuticals: imipramine, chlorpromazine, nicotine and methionine. Int J Appl Radiat Isot 1979;30 (7):393–399

    Article  PubMed  CAS  Google Scholar 

  28. Cizek J, Herholz K, Vollmar S, Schrader R, Klein J, Heiss WD. Fast and robust registration of PET and MR images of human brain. Neuroimage 2004;22 (1):434–442

    Article  PubMed  Google Scholar 

  29. Galldiks N, Burghaus L, Vollmar S, Cizek J, Impekoven P, Thomas A, Jacobs AH, Herholz K. Novel Neuroimaging Findings in a Patient with Cerebral Whipple’s Disease: A Magnetic Resonance Imaging and Positron Emission Tomography Study. J Neuroimaging 2004;14 (4):372–376

    Article  PubMed  CAS  Google Scholar 

  30. Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957;2 (5):200–215

    PubMed  CAS  Google Scholar 

  31. Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke 1988;19 (12):1497–1500

    PubMed  CAS  Google Scholar 

  32. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8 (7):1277–1280

    PubMed  CAS  Google Scholar 

  33. Chang SM, Theodosopoulos P, Lamborn K, Malec M, Rabbitt J, Page M, Prados MD. Temozolomide in the treatment of recurrent malignant glioma. Cancer 2004;100 (3):605–611

    Article  PubMed  CAS  Google Scholar 

  34. Yung WK, Prados MD, Yaya–Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17 (9):2762–2771

    PubMed  CAS  Google Scholar 

  35. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994;34 (1):45–60

    Article  PubMed  CAS  Google Scholar 

  36. Roelcke U, Radu E, Ametamey S, Pellikka R, Steinbrich W, Leenders KL. Association of rubidium and C–methionine uptake in brain tumors measured by positron emission tomography. J Neurooncol 1996;27 (2):163–171

    Article  PubMed  CAS  Google Scholar 

  37. Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S. Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 2005;71 (2):161–168

    Article  PubMed  CAS  Google Scholar 

  38. Ribom D, Schoenmaekers M, Engler H, Smits A. Evaluation of 11C–methionine PET as a surrogate endpoint after treatment of grade 2 gliomas. J Neurooncol 2005;71 (3):325–332

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK

    Norbert Galldiks, Lutz W. Kracht, Lothar Burghaus, Anne Thomas, Andreas H. Jacobs, Wolf–Dieter Heiss & Karl Herholz

Authors
  1. Norbert Galldiks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lutz W. Kracht
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lothar Burghaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anne Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andreas H. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wolf–Dieter Heiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Karl Herholz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl Herholz.

Additional information

N. Galldiks and L.W. Kracht contributed equally to this paper

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galldiks, N., Kracht, L.W., Burghaus, L. et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 33, 516–524 (2006). https://doi.org/10.1007/s00259-005-0002-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-0002-5

Keywords

Search

Navigation